ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 006,22
0,42%
Dow Jones
44 470,41
0,38%
DAX
21 911,74
0,68%
Brent Oil
75,93
1,76%
Bitcoin
97 358,26
0,90%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Akero Therapeutics Inc (AKRO)

  7. Akero Therapeutics Inc (AKRO) Actualités

AKRO

Akero Therapeutics (AKRO)

Akero Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AKRO
DateHeureSourceTitreSymboleSociété
08/02/202501h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
30/01/202522h05GlobeNewswire Inc.Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:AKROAkero Therapeutics Inc
30/01/202513h52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKROAkero Therapeutics Inc
29/01/202523h08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AKROAkero Therapeutics Inc
29/01/202503h30GlobeNewswire Inc.Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:AKROAkero Therapeutics Inc
28/01/202503h35Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:AKROAkero Therapeutics Inc
27/01/202522h24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKROAkero Therapeutics Inc
27/01/202522h01GlobeNewswire Inc.Akero Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:AKROAkero Therapeutics Inc
27/01/202512h30GlobeNewswire Inc.Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY StudyNASDAQ:AKROAkero Therapeutics Inc
24/01/202522h05GlobeNewswire Inc.Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASHNASDAQ:AKROAkero Therapeutics Inc
24/01/202517h01PR Newswire (US)Kuehn Law Encourages Investors of Akero Therapeutics, Inc. to Contact Law FirmNASDAQ:AKROAkero Therapeutics Inc
13/01/202513h00GlobeNewswire Inc.Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLDNASDAQ:AKROAkero Therapeutics Inc
07/01/202513h00GlobeNewswire Inc.Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AKROAkero Therapeutics Inc
26/11/202413h00GlobeNewswire Inc.Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:AKROAkero Therapeutics Inc
15/11/202417h00GlobeNewswire Inc.Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024NASDAQ:AKROAkero Therapeutics Inc
13/11/202422h05GlobeNewswire Inc.Akero Therapeutics to Present at the Jefferies London Healthcare ConferenceNASDAQ:AKROAkero Therapeutics Inc
08/11/202413h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AKROAkero Therapeutics Inc
08/11/202413h00GlobeNewswire Inc.Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AKROAkero Therapeutics Inc
21/10/202413h00GlobeNewswire Inc.Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024NASDAQ:AKROAkero Therapeutics Inc
01/10/202403h37PR Newswire (US)INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law FirmNASDAQ:AKROAkero Therapeutics Inc
30/09/202413h00GlobeNewswire Inc.Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual ConferenceNASDAQ:AKROAkero Therapeutics Inc
09/09/202413h00GlobeNewswire Inc.Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASHNASDAQ:AKROAkero Therapeutics Inc
28/08/202422h05GlobeNewswire Inc.Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:AKROAkero Therapeutics Inc
09/08/202413h00GlobeNewswire Inc.Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AKROAkero Therapeutics Inc
11/06/202413h00GlobeNewswire Inc.Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASHNASDAQ:AKROAkero Therapeutics Inc
08/06/202414h15GlobeNewswire Inc.Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024NASDAQ:AKROAkero Therapeutics Inc
29/05/202413h00GlobeNewswire Inc.Akero Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:AKROAkero Therapeutics Inc
10/05/202422h57Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:AKROAkero Therapeutics Inc
10/05/202413h00GlobeNewswire Inc.Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AKROAkero Therapeutics Inc
08/05/202413h00GlobeNewswire Inc.Akero Therapeutics to Present at the BofA Securities 2024 Health Care ConferenceNASDAQ:AKROAkero Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AKRO

Dernières Valeurs Consultées

TG
34Q0
Quantum eMotion
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces